Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes

Objective Testosterone is a commonly abused androgen in sports and in the gym culture of the society. Its abuse is conventionally disclosed by urinary assay of the testosterone/epitestosterone (T/E) glucuronide ratio, which should not exceed 4. A noteworthy number of athletes, however, have higher natural ratios than 4, most likely because of decreased excretion of epitestosterone glucuronide. Falsely positive doping test results are of great concern for the legal rights of the sportsman. Our objective was to study the genetic aspects of epitestosterone formation, and to elucidate the impact of genetic variation in androgen-metabolizing enzymes. Methods Urine from different study populations was analysed for androgen glucuronides by gas chromatography-mass spectrometry. All men were genotyped for the uridine diphospho-glucuronosyltransferase (UGT) 2B17 deletion polymorphism and single nucleotide polymorphisms in the cytochrome P-450c17&agr; (CYP17), UGT2B15 and UGT2B7 genes. Expression of UGT2B15 mRNA in human liver samples was analysed using real-time PCR. Results A T>C (A1>A2) promoter polymorphism in the CYP17 gene was associated with the urinary glucuronide levels of epitestosterone and its putative precursor androstene-3&bgr;, 17&agr;-diol, resulting in 64% higher T/E ratios in A1/A1 homozygotes. Individuals devoid of UGT2B17 had significantly higher UGT2B15 mRNA levels in liver than individuals carrying two functional UGT2B17 alleles. Conclusion The CYP17 promoter polymorphism may partly explain high natural (>4) T/E ratios. Our data indicate that 5-androstene-3&bgr;, 17&agr;-diol is an important precursor of epitestosterone and that CYP17 is involved in its production. In addition, we found that lack of the UGT2B17 enzyme may be compensated for by increase in UGT2B15 transcription.

[1]  L. Ekström,et al.  The UGT2B17 gene deletion is not associated with prostate cancer risk , 2008, The Prostate.

[2]  L. Ekström,et al.  Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate , 2008, The Pharmacogenomics Journal.

[3]  C. Swanson,et al.  Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). , 2007, The Journal of clinical endocrinology and metabolism.

[4]  J. Heracek,et al.  Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer , 2007, Steroids.

[5]  K. Knights,et al.  The Glucuronidation of Δ4-3-Keto C19- and C21-Hydroxysteroids by Human Liver Microsomal and Recombinant UDP-glucuronosyltransferases (UGTs): 6α- and 21-Hydroxyprogesterone Are Selective Substrates for UGT2B7 , 2007, Drug Metabolism and Disposition.

[6]  C. Swanson,et al.  BRIEF REPORT The Uridine Diphosphate Glucuronosyltransferase 2B15 D 85 Y and 2B17 Deletion Polymorphisms Predict the Glucuronidation Pattern of Androgens and Fat Mass in Men , 2007 .

[7]  O. Barbier,et al.  Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. , 2006, Endocrinology.

[8]  T. Sellers,et al.  Deletion Polymorphism of UDP-Glucuronosyltransferase 2B17 and Risk of Prostate Cancer in African American and Caucasian Men , 2006, Cancer Epidemiology Biomarkers & Prevention.

[9]  Claes Ohlsson,et al.  Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  T. A. Bell,et al.  Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. , 2004, Genomics.

[11]  Mohamed Helal,et al.  Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. , 2004, The Journal of urology.

[12]  M. Eichelbaum,et al.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real‐rime PCR , 2003, Human mutation.

[13]  O. Barbier,et al.  Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans , 2003, Trends in Endocrinology & Metabolism.

[14]  C. Guillemette,et al.  Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[16]  D. Hum,et al.  Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. , 2001, Endocrinology.

[17]  B. Chung,et al.  Biochemical roles of testosterone and epitestosterone to 5 alpha-reductase as indicators of male-pattern baldness. , 2001, The Journal of investigative dermatology.

[18]  J. Miners,et al.  Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. , 2000, Pharmacogenetics.

[19]  D. Borts,et al.  Direct measurement of urinary testosterone and epitestosterone conjugates using high-performance liquid chromatography/tandem mass spectrometry. , 2000, Journal of mass spectrometry : JMS.

[20]  C. Wadelius,et al.  Prostate cancer associated with CYP17 genotype. , 1999, Pharmacogenetics.

[21]  K. Livak,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay. , 1999, Genetic analysis : biomolecular engineering.

[22]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .

[23]  T. Tephly,et al.  The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  M. Green,et al.  Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. , 1997, Pharmacogenetics.

[25]  C. Ayotte,et al.  Testing for natural and synthetic anabolic agents in human urine. , 1996, Journal of chromatography. B, Biomedical applications.

[26]  I. Björkhem,et al.  Increased urinary testosterone/epitestosterone ratios found in Swedish athletes in connection with a national control program. Evaluation of 28 cases. , 1996, Journal of chromatography. B, Biomedical applications.

[27]  I. Björkhem,et al.  Serum and urinary markers of exogenous testosterone administration , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  J. Little,et al.  Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. , 1994, Human molecular genetics.

[29]  L. Dehennin.  On the origin of physiologically high ratios of urinary testosterone to epitestosterone: consequences for reliable detection of testosterone administration by male athletes. , 1994, The Journal of endocrinology.

[30]  D. Cowan,et al.  Potential use of ketoconazole in a dynamic endocrine test to differentiate between biological outliers and testosterone use by athletes. , 1993, Clinical chemistry.

[31]  L. Dehennin.  Secretion by the human testis of epitestosterone, with its sulfoconjugate and precursor androgen 5-androstene-3β,17α-diol , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  A. Matsumoto,et al.  Long-term administration of testosterone enanthate to normal men: Alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  L. Dehennin.  Secretion by the human testis of epitestosterone, with its sulfoconjugate and precursor androgen 5-androstene-3 beta,17 alpha-diol. , 1993, The Journal of steroid biochemistry and molecular biology.

[34]  J. Brun,et al.  False-positive cases in detection of testosterone doping , 1992, The Lancet.

[35]  M. Wheeler,et al.  Criteria to indicate testosterone administration. , 1990, British journal of sports medicine.

[36]  J Park,et al.  Drug testing at the 10th Asian Games and 24th Seoul Olympic Games. , 1990, Journal of analytical toxicology.

[37]  B. Chung,et al.  Analysis of anabolic steroids using GC/MS with selected ion monitoring. , 1990, Journal of analytical toxicology.

[38]  R. Hampl,et al.  Epitestosterone--an endogenous antiandrogen? , 1989, Journal of steroid biochemistry.

[39]  T. Benraad,et al.  The mechanism of the synthesis of 16-androstenes in human testicular homogenates. , 1989, Journal of steroid biochemistry.

[40]  W. Miller,et al.  Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. , 1987, DNA.